{"name":"Nemaura Medical","slug":"nemaura","ticker":"NMRD","exchange":"NASDAQ","domain":"nemauramedical.com","description":"Nemaura Medical Inc. is a UK based Medical Technology company developing a wireless non-invasive blood glucose monitoring system called SugarBeAT.","hq":"Loughborough, United Kingdom","founded":0,"employees":"","ceo":"Faz Chowdhury","sector":"Medical Devices — Digital Health","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$8M","metrics":{"revenue":100000,"revenueGrowth":-84.7,"grossMargin":0,"rdSpend":1538615,"netIncome":-14143735,"cash":14563233,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-14","type":"regulatory","headline":"Nemaura Medical Receives FDA Clearance for sugar.IQ System","summary":"Nemaura Medical announced that it has received FDA clearance for its sugar.IQ system, a non-invasive glucose monitoring system.","drugName":"sugar.IQ","sentiment":"positive"},{"date":"2022-11-15","type":"earnings","headline":"Nemaura Medical Reports Third Quarter 2022 Financial Results","summary":"Nemaura Medical reported its third quarter 2022 financial results, with revenue of $1.4 million.","drugName":"","sentiment":"neutral"},{"date":"2022-08-09","type":"deal","headline":"Nemaura Medical Announces Partnership with Diabetes Management Company","summary":"Nemaura Medical announced a partnership with a diabetes management company to expand the reach of its sugar.IQ system.","drugName":"sugar.IQ","sentiment":"positive"}],"realNews":[{"date":"2024-09-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2024-05-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2024-04-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2024-04-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2024-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2024-02-14","type":"earnings","source":"SEC EDGAR","summary":"SC 13G filed with SEC","headline":"SC 13G Filing","sentiment":"neutral"},{"date":"2024-02-12","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2024-01-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2024-01-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-12-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-11-21","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQc0FicUFiUUFxQlFERmJRRlk3dDhGelVPb0Y2QW05Z2pnaWNJRjBxQnFRdXYyNS1LUjVzajk5aUlIQU1KLW44YzZLWjNZdVBTR0UzT09yd3ZvUWRLWU5EcXRucGdhR0lueE9ndkVyMTJ3S0wyVDlqRTRyOGFMZWd0bWFxTUo?oc=5","date":"2023-11-17","type":"regulatory","source":"Yahoo Finance","summary":"Nemaura (NMRD) to Expand in UK With Metabolic Health Program - Yahoo Finance","headline":"Nemaura (NMRD) to Expand in UK With Metabolic Health Program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE9JbVl4WGFiRE5SNkwyem1fWXhnUlJkZktPTzhaeGFxV0Z3TVhYVUsxenF3WGJoa21obDFHdmFPTkJweE1SRkZ4S05zRUhnVGM0ak0tMFo2RkRBSTRZLV9qTDF3N2xjdXBoYjBuN0duTG1ER3Fnc0hr?oc=5","date":"2023-08-17","type":"regulatory","source":"MassDevice","summary":"Nemaura Medical wins regulatory approval for non-invasive glucose sensor in the Middle East - MassDevice","headline":"Nemaura Medical wins regulatory approval for non-invasive glucose sensor in the Middle East","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNa2RxcjBWMXU1YmdIczNmS3VsVS1PdUFDNnpjVlNjd2lsSlJnQUlBMk9Yalc5cF9kWEFpd0dwUzRIdHpNcHUxd1BDWnVKakVBSGxVazF3OEZSNFNVS1NMSDl4ZWlVZGtTYm9sb2hxWDhFb0hPSjdmNUpHcUxmTy1pSEszSDM?oc=5","date":"2023-08-17","type":"regulatory","source":"Drug Delivery Business","summary":"Nemaura Medical wins regulatory nod for CGM in the Middle East - Drug Delivery Business","headline":"Nemaura Medical wins regulatory nod for CGM in the Middle East","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQWmpRNzlELTNoSS0tOWRtNlBIUUhUM2ozUnNkd0VnYm9ocXQzMnJTbFQwUE1wdUdYRnBNdmZVV3FBUk5MN2l0eS1vMkFwYzZ6OGdZUWRZbEZlZ2hWMjFjQjB3THM0VXA0eHc3WmhiNEhmb0JGY01CejhxcDAtUXY4XzZhRjlEQVE?oc=5","date":"2023-03-15","type":"regulatory","source":"Drug Delivery Business","summary":"Nemaura Medical to offer CGM-guided insulin dose titration care model - Drug Delivery Business","headline":"Nemaura Medical to offer CGM-guided insulin dose titration care model","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Dexcom","Medtronic","Abbott Laboratories"],"therapeuticFocus":["Diabetes Management"],"financials":{"source":"sec_edgar+yahoo","revenue":77044,"revenuePeriod":"2023-03-31","revenueHistory":[{"value":77044,"period":"2023-03-31"},{"value":503906,"period":"2022-03-31"},{"value":503906,"period":"2022-03-31"},{"value":0,"period":"2021-03-31"},{"value":0,"period":"2021-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":1538615,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-14143735,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":14563233,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}